Please ensure Javascript is enabled for purposes of website accessibility

A few weeks ago, while I was in India for Vitafoods India, I spoke about the health benefits of an ingredient I have included in my metabolic health content. I am now writing a blog about the latest findings with CQR-300® and the buzz around GLP-1. The latest study shows how and why it impacts GLP-1 levels.[i]

In the ever-evolving world of natural health supplements, CQR-300® has emerged as a game-changer in weight management and metabolic wellness. Derived from the Cissus quadrangularis plant, this patented extract is clinically proven to support healthy body weight, fat metabolism, and overall metabolic balance. A recent 12-week clinical study sheds light on its remarkable effectiveness in promoting weight loss and improving metabolic parameters.

Let’s explore the science behind CQR-300®, its mechanisms of action, and how it can help individuals achieve their weight and health goals.

What Is CQR-300®?

CQR-300® is a patented and clinically validated extract of Cissus quadrangularis, a plant traditionally used in Ayurvedic and African medicine. It is packed with bioactive compounds such as phytosterols, carotenoids, tannins, and phenols and is known for its cholesterol-lowering and antioxidant properties.

Unlike many weight management supplements that rely on stimulants, CQR-300® takes a unique, multifaceted approach. It naturally enhances the body’s ability to regulate appetite, digestion, and metabolism.

How CQR-300® Works

The latest study highlights CQR-300®’s ability to modulate key metabolic pathways that influence weight and fat metabolism:

Boosts GLP-1 Levels for Better Blood Sugar Control

  • CQR-300® inhibits dipeptidyl peptidase-4 (DPP-4), an enzyme that degrades glucagon-like peptide-1 (GLP-1).
  • Prolonging GLP-1 activity enhances insulin production, reduces glucagon secretion, and improves blood sugar regulation.
  • In the latest study, GLP-1 levels increased by 56% in the CQR-300® group compared to just 15% in the control group.

Supports Appetite Control and Satiety

  • CQR-300® restores sensitivity to leptin and adiponectin, two key hormones that control hunger and satiety.
  • Participants in the study reported a 20% reduction in calorie intake compared to just 3 in the control group.

Inhibits Fat & Carbohydrate Absorption

CQR-300® blocks the activity of enzymes like lipase, α-amylase, and α-glucosidase, which are responsible for digesting fats and carbohydrates.

This mechanism reduces calorie absorption, promoting weight loss and metabolic balance.

Clinical Study Results: A New Standard in Weight Management

A 12-week randomized, controlled study on 90 overweight or obese adults delivered impressive results:

  • 14% reduction in body weight vs. 1% in the control group.
  • 27% reduction in body fat percentage vs. minimal change in the control group.
  • 54% decrease in DPP-4 levels, compared to a 129% increase in the control group.
  • Significant improvements in blood pressure, cholesterol levels, triglycerides, and fasting blood glucose.

These findings confirm that CQR-300® is not just another weight loss supplement—it is a clinically backed ingredient with profound metabolic benefits.

Who Can Benefit from CQR-300?

CQR-300 is ideal for individuals looking for natural, non-stimulant support in managing:

✅ Weight loss and body composition

✅ Appetite and cravings

✅ Blood sugar and insulin sensitivity

✅ Cholesterol and triglyceride levels

✅ Overall metabolic health

Parting Thoughts

The latest 12-week clinical trial reinforces CQR-300®’s role as a powerful, science-backed ingredient for weight management and metabolic health. By boosting GLP-1, inhibiting DPP-4, and improving satiety, it offers a natural and effective way to support healthy body composition and metabolism.

 

 

 

[i]

Cissus quadrangularis (CQR-300®) and Dichrostachys glomerata (Dyglomera®) extracts increase GLP-1 and inhibit DPP-4 in overweight and obese adults. Presentation abstract, 32nd International Conference of the Function Food Center, October 2024.